SCHEMBL2658318

SCHEMBL2658318

COc1ccc(F)cc1-c1cccc2c(N)c3c(nc12)CN(C1=CC=C1)C3=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 11/20 0.37
▸ GABRB3 P28472 11/20 0.37
▸ GABRA2 P47869 11/20 0.37
▸ BACE1 P56817 1/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ CREBBP Q92793 1/20 0.35
▸ ENPP3 O14638 1/20 0.34
▸ ENPP1 P22413 1/20 0.34
▸ RPS6KA2 Q15349 1/20 0.34
▸ GABRA1 P14867 1/20 0.33
▸ GABRA5 P31644 1/20 0.33
▸ GABRA3 P34903 1/20 0.33
▸ UGCG Q16739 1/20 0.33
▸ NR3C1 P04150 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ NR3C2 P08235 1/20 0.33
▸ AR P10275 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CCNT1 O60563 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657086 0.93 UGCG (0.36) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL2658032 0.91 UGCG (0.33) GABRG2GABRB3GABRA2BACE1RPS6KA2
SCHEMBL2655753 0.91 UGCG (0.39) GABRG2GABRB3GABRA2DPP4UGCG
SCHEMBL4912616 0.90 GABRG2 (0.48) GABRG2GABRB3GABRA2BACE1ENPP3
SCHEMBL2660785 0.90 GABRG2 (0.43) GABRG2GABRB3GABRA2ENPP3ENPP1
SCHEMBL2655981 0.89 CRHR1 (0.38) GABRG2GABRB3GABRA2DPP4ENPP3
SCHEMBL2658971 0.88 GABRG2 (0.39) GABRG2GABRB3GABRA2BACE1DPP4
SCHEMBL2657233 0.87 GABRA1 (0.43) GABRG2GABRB3GABRA2RPS6KA2GABRA1
SCHEMBL2657791 0.85 GABRG2 (0.43) GABRG2GABRB3GABRA2UGCG
SCHEMBL4919724 0.85 CRHR1 (0.41) GABRG2GABRB3GABRA2ENPP3ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback